Sign In
Buy VERA
$31.58
-1.31 (-3.98%)
At Close: Aug 10, 2026
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Rating of “Moderate Buy” from Brokerages
02:38am, Thursday, 23'rd Oct 2025
Vera Therapeutics, Inc. (NASDAQ: VERA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eleven analysts that are presently covering the stock, Marketbeat Ratings repo
Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET
08:00am, Wednesday, 22'nd Oct 2025
BRISBANE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme
BRISBANE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 10'th Oct 2025
BRISBANE, Calif., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on October 6, 2025, the Compensation Committee of the Board of Directors of Vera Therap
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 05'th Sep 2025
BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera's Board of Directors granted
Vera Therapeutics, Inc. (VERA) Presents at Cantor Global Healthcare Conference 2025 Transcript
05:45am, Friday, 05'th Sep 2025
Vera Therapeutics, Inc. (NASDAQ:VERA ) Cantor Global Healthcare Conference 2025 September 4, 2025 9:10 AM EDT Company Participants Marshall Fordyce - Founder, President, CEO & Director Robert Brenner
Vera Therapeutics to Participate at Upcoming Investor Conferences
04:05pm, Tuesday, 26'th Aug 2025
BRISBANE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 08'th Aug 2025
BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera's Board of Directors granted indu
Vera (VERA) Q2 Net Loss Widens 127%
02:05am, Wednesday, 06'th Aug 2025
Vera Therapeutics (VERA 0.93%), a biotechnology company developing treatments for serious immunologic diseases, released results for the quarter on August 5, 2025. The most notable news was its wideni
Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
07:00am, Tuesday, 05'th Aug 2025
On track to submit a Biologics License Application (BLA) for accelerated approval of atacicept to U.S. FDA in Q4 2025; potential commercial launch in 2026 Announced positive primary endpoint results f
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:05pm, Thursday, 10'th Jul 2025
BRISBANE, Calif. , July 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 6, 2025, the Compensation Committee granted inducement awards consisting of non
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
01:58pm, Thursday, 12'th Jun 2025
The biopharmaceuticals industry is both exciting and risky for investors. Many leading growth stocks in the U.S. market are found in this sector, due to the significant rallies that biopharmaceutic
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 09'th Jun 2025
BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of non-
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
04:05pm, Wednesday, 04'th Jun 2025
BRISBANE, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans
06:30am, Tuesday, 03'rd Jun 2025
BRISBANE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatment
